Israel
· Delayed Price · Currency is ILS · Price in ILALineage Cell Therapeutics Statistics
Total Valuation
Lineage Cell Therapeutics has a market cap or net worth of ILS 448.45 million. The enterprise value is 334.14 million.
| Market Cap | 448.45M |
| Enterprise Value | 334.14M |
Important Dates
The next estimated earnings date is Thursday, March 13, 2025.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.29% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 177.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 13.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.47 |
| EV / Sales | 10.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.90 |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.48 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.50% and return on invested capital (ROIC) is -17.48%.
| Return on Equity (ROE) | -30.50% |
| Return on Assets (ROA) | -11.84% |
| Return on Capital (ROIC) | -17.48% |
| Revenue Per Employee | 450,155 |
| Profits Per Employee | -1.04M |
| Employee Count | 75 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -50.46% |
| 50-Day Moving Average | 267.90 |
| 200-Day Moving Average | 352.45 |
| Relative Strength Index (RSI) | 34.64 |
| Average Volume (20 Days) | 43,857 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.70 |
Income Statement
In the last 12 months, Lineage Cell Therapeutics had revenue of ILS 32.41 million and -74.76 million in losses. Loss per share was -0.41.
| Revenue | 32.41M |
| Gross Profit | 41.01M |
| Operating Income | -71.37M |
| Pretax Income | -74.52M |
| Net Income | -74.76M |
| EBITDA | -69.02M |
| EBIT | -71.37M |
| Loss Per Share | -0.41 |
Balance Sheet
The company has 121.60 million in cash and 10.22 million in debt, giving a net cash position of 111.37 million.
| Cash & Cash Equivalents | 121.60M |
| Total Debt | 10.22M |
| Net Cash | 111.37M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 240.86M |
| Book Value Per Share | 1.30 |
| Working Capital | 76.34M |
Cash Flow
In the last 12 months, operating cash flow was -84.62 million and capital expenditures -1.08 million, giving a free cash flow of -85.71 million.
| Operating Cash Flow | -84.62M |
| Capital Expenditures | -1.08M |
| Free Cash Flow | -85.71M |
| FCF Per Share | n/a |
Margins
Gross margin is 126.54%, with operating and profit margins of -220.21% and -230.66%.
| Gross Margin | 126.54% |
| Operating Margin | -220.21% |
| Pretax Margin | -229.91% |
| Profit Margin | -230.66% |
| EBITDA Margin | -212.95% |
| EBIT Margin | -220.21% |
| FCF Margin | n/a |
Dividends & Yields
Lineage Cell Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.29% |
| Shareholder Yield | -7.29% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Lineage Cell Therapeutics has an Altman Z-Score of -2.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.42 |
| Piotroski F-Score | n/a |